Savella in Treatment for Provoked Vestibulodynia

Exclusion Criteria

• •1. other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, and atrophic vaginitis (presence of a maturation index),
• •2. previous vestibulectomy,
• •3. active vaginal infection,
• •4. neuropathology, including seizure disorder or syncopal episodes,
• •5. pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study,
• •6. breastfeeding,
• •7. major medical illness including chronic liver disease/hepatic impairment, renal impairment, narrow-angle glaucoma, or uncontrolled hypertension,
• •8. major psychiatric illness including substance abuse,
• •9. multiple allergies (greater than three drugs or environmental agents),
• •10. use of centrally-acting agents, including monoamine oxidase inhibitors, benzodiazepines, opiates, muscle relaxants, and antidepressants within 2 weeks of randomization and during the study, and
• •11. use of topical lidocaine, within 2 weeks of randomization and during the study, as it has shown to be an effective treatment in some women, while worsening symptoms in others. Subjects will be permitted to take acetaminophen, aspirin, or a nonsteroidal anti-inflammatory drug as rescue medication. They will be provided with a list of allowable escape medications and those which would constitute a protocol deviation.